Form 4: Amicus Therapeutics Director Michael Raab Reports Acquisition of Stock Options and Restricted Stock Units

Director Michael Raab reports acquisition of stock options and restricted stock units in Amicus Therapeutics.

Summary

• Michael Raab, a director of Amicus Therapeutics, reported changes in beneficial ownership on June 6, 2024.
• Raab acquired 11,847 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.00.
• These RSUs will vest in full on the one-year anniversary of the grant date and are payable in Amicus common stock.
• One RSU is equivalent to one share of Amicus common stock.
• Raab also acquired 42,467 stock options with an exercise price of $10.27, expiring on June 6, 2034.
• These options vest and become exercisable on the one-year anniversary of the grant date.
• Following these transactions, Raab directly owns 95,443 shares of common stock and 42,467 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock and option grants to a director. It indicates alignment of interests but doesn't necessarily reflect a major positive or negative outlook.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The RSUs will vest in one year, converting into common stock. The stock options will also vest in one year, becoming exercisable at $10.27 per share.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares and options by a director can be viewed positively by shareholders, as it aligns the director's interests with those of the shareholders.

Key Dates